安科生物跌2.07%，成交额2.38亿元，主力资金净流出3198.84万元

Core Viewpoint - Anke Biological experienced a stock price decline of 2.07% on August 22, with a current price of 11.38 yuan per share and a total market capitalization of 19.033 billion yuan [1] Company Overview - Anhui Anke Biological Engineering (Group) Co., Ltd. was established on September 28, 2000, and listed on October 30, 2009. The company specializes in research, development, production, and sales of biotechnological products, including cell engineering, gene engineering, gene testing, and precision medicine [1] - The main revenue composition includes 88.24% from gene engineering drugs, 11.67% from external patches, and 0.09% from other sources [1] Financial Performance - For the first half of 2025, Anke Biological reported operating revenue of 1.292 billion yuan, a year-on-year decrease of 0.51%, and a net profit attributable to shareholders of 367 million yuan, down 11.92% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 2.662 billion yuan, with 1.252 billion yuan distributed in the last three years [3] Shareholder Structure - As of June 30, 2025, the number of shareholders is 65,700, a decrease of 2.17% from the previous period, with an average of 18,598 circulating shares per person, an increase of 2.22% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder, holding 20.7916 million shares, an increase of 7.341 million shares from the previous period [3]